Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Karmali R, et al. Among authors: badar t. Am J Hematol. 2021 Nov 1;96(11):1374-1384. doi: 10.1002/ajh.26306. Epub 2021 Aug 10. Am J Hematol. 2021. PMID: 34324220 Free PMC article.
Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study.
Pritzl SL, Gurney M, Badar T, Ferrer A, Lasho T, Finke C, Mangaonkar A, McCullough K, Gangat N, Fernandez J, Al-Kali A, Viswanatha D, He R, Foran J, Patnaik MM. Pritzl SL, et al. Among authors: badar t. Leuk Res. 2023 Feb;125:107007. doi: 10.1016/j.leukres.2022.107007. Epub 2022 Dec 28. Leuk Res. 2023. PMID: 36586169 No abstract available.
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, Litzow MR, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. Hiwase D, et al. Among authors: badar t. Blood. 2023 Mar 2;141(9):1087-1091. doi: 10.1182/blood.2022018236. Blood. 2023. PMID: 36574363 Free article. No abstract available.
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.
Al-Kali A, Nanaa A, Viswanatha D, He R, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB. Al-Kali A, et al. Among authors: badar t. Blood Cancer J. 2023 Apr 10;13(1):49. doi: 10.1038/s41408-023-00818-6. Blood Cancer J. 2023. PMID: 37032414 Free PMC article. No abstract available.
Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.
Badar T, Nanaa A, Foran JM, Viswanatha D, Al-Kali A, Lasho T, Finke C, Alkhateeb HB, He R, Gangat N, Shah M, Tefferi A, Mangaonkar AA, Litzow MR, Ongie LJ, Chlon T, Ferrer A, Patnaik MM. Badar T, et al. Haematologica. 2023 Nov 1;108(11):3033-3043. doi: 10.3324/haematol.2023.282867. Haematologica. 2023. PMID: 37199125 Free PMC article. Review.
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Abdallah M, McCullough K, Ilyas R, Begna KH, Al-Kali A, Litzow MR, Hogan WJ, Mangaonkar A, Alkhateeb H, Shah MV, Elliott MA, Foran JM, Badar T, Palmer JM, Yi CA, Sproat L, Pardanani A, Patnaik MM, Olteanu H, Ketterling RP, Tefferi A, Gangat N. Abdallah M, et al. Among authors: badar t. Blood Cancer J. 2023 Mar 13;13(1):35. doi: 10.1038/s41408-023-00812-y. Blood Cancer J. 2023. PMID: 36907917 Free PMC article. No abstract available.
Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm.
Gangat N, Ilyas R, McCullough K, Begna KH, Al-Kali A, Patnaik MM, Litzow MR, Hogan WJ, Mangaonkar A, Alkhateeb H, Shah MV, Elliott MA, Foran JM, Badar T, Palmer JM, Hanson CA, Pardanani A, Tefferi A. Gangat N, et al. Among authors: badar t. Haematologica. 2023 May 1;108(5):1423-1428. doi: 10.3324/haematol.2022.282019. Haematologica. 2023. PMID: 36519330 Free PMC article. No abstract available.
92 results